Drug Trial News

RSS

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

5 Nov 2015

Drugs that target malignant cells increase life expectancy in advanced breast cancer patients

Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.

5 Nov 2015

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Pancreas cancer remains one of the deadliest cancers worldwide. In the United States, it accounts for only three percent of all diagnosed cancers but it causes almost seven percent of all cancer deaths. A pancreas cancer diagnosis often comes after age 50 and after the cancer has spread, making it difficult to remove surgically.

4 Nov 2015

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

4 Nov 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment.

4 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders.

30 Oct 2015

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

30 Oct 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Brief exposure to general anesthesia during infancy does not affect neurological development

Although the medical community has raised concerns about the safety of anesthesia on the developing brains of young children, new research presented at the ANESTHESIOLOGY 2015 annual meeting, found brief exposure to general anesthesia during infancy did not impair neurological development. This is the first prospective, randomized, controlled clinical trial to assess the long-term, neurological effects of anesthesia in children.

27 Oct 2015

Drug Trial News

Diabetes drug liraglutide ineffective in patients with advanced heart failure

Viralytics enters into clinical trial collaboration agreement with MSD

Hutchison MediPharma begins sulfatinib Phase I trial in US

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Drugs that target malignant cells increase life expectancy in advanced breast cancer patients

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Brief exposure to general anesthesia during infancy does not affect neurological development

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News